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NMR-based prediction of cardiovascular risk in diabetes 
 
To the editor: 
It has been proposed that nuclear magnetic resonance (NMR) plasma analysis can improve 
lipoprotein subclass discrimination and predict coronary artery disease (CAD)1. In the recent 
paper by Kirschenlohr et al.2, it was concluded that proton NMR spectroscopy shows only 
weak discrimination for detecting angiography-defined CAD. An even more important 
question is whether proton NMR spectroscopy is able to predict cardiovascular events. 
Indeed, the mortality and morbidity for CAD in type 2 diabetes patients is two to four times 
higher than in nondiabetic subjects3, making cardiovascular disease the first cause of death 
and disability amongst this population. Moreover, CAD is often undetected in diabetic 
patients. The traditional risk factors do not fully explain the level of the cardiovascular risk in 
these patients, and new tools are being developed to better identify high-risk patients, who 
need invasive coronary evaluation and/or aggressive treatments. Indeed, the strategy must 
have a high degree of accuracy for detecting CAD, owing to the potential morbidity 
associated with angiographic procedures. 
To assess whether NMR spectroscopy can predict cardiovascular disease, we 
performed a case-control study nested in the placebo arm of a larger clinical trial, 
DIABHYCAR (ref. 4). DIABHYCAR, a randomized clinical trial, involved high-risk type 2 
diabetic patients who were followed for 4 years and who, during that period, had fatal or 
nonfatal acute myocardial infarction. The study protocol was approved by the ethical 
committee of Angers University, France. All participants provided written informed consent. 
This nested case-control study included 190 patients (150 men and 40 women). We acquired 
proton NMR spectra of samples collected from patients upon their inclusion in 
DIABHYCAR. Patients of the ‘case’ group were defined as those who presented either a fatal 
or nonfatal acute myocardial infarction or who underwent sudden death during the 4-year 
follow-up. Control patients were defined as patients not presenting any cardiovascular events. 
Control patients were matched to the case patients for age ± 2 years, sex and geographical 
origin, and their follow-up lasted for at least as long as that of the case patients (Table 1). We 
obtained blood samples after an overnight fast, using tubes without anticoagulant. We stored 
sera at –80 °C before NMR analysis. We acquired spectra at 500 MHz (Varian Inova) with a 
1.5-s presaturation of the water signal5. The acquisition sequence consisted of a 4-s-long 
relaxation delay (including water suppression delay) and a 90° excitation pulse. The signal 
was acquired on 16,384 data points. Fourier transform was applied without zero filling, and 
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with a 0.1 Hz line-broadening factor. The chemical shift scale was calibrated on the fumaric 
acid signal at 6.53 p.p.m. 
We used two distinct methods to analyze the spectrum: determination of lipid 
subclasses by deconvolution in the frequency domain (method 1) and whole-spectra  analysis 
(method 2). More specifically, for method 1, lipoprotein deconvolution was performed with 
WINNMR software as described previously5. Briefly, the region between 0.5 and 1.1 p.p.m. 
was deconvoluted into 11 Lorentzians whose areas were used for multivariate analysis. In 
method 2, the spectra were divided into bins of width 0.04 p.p.m., defined from 10 to 0.4 
p.p.m., excluding the water signal between 4.9 to 4.5 p.p.m. This data reduction resulted in 
207 elements for each spectrum1. 
To the results of each method, we then applied orthogonal signal correction (OSC) 
followed by partial least-squares discriminant analysis (PLS-DA), a similar approach to the 
one used previously1. This statistical analysis was performed twice: first on the complete set 
of 190 patients of the nested case-control study and then, to evaluate the model predictability 
on an independent population, on a randomly chosen training group (70% of the subjects) and 
validation group (30%). To classify the patients of this validation group, we applied the model 
obtained from the OSC/PLS-DA analysis of the training group to the spectra of the validation 
group.  
The OSC/PLS-DA model, which was based on the 11 elements (Lorentzian) obtained 
by lipid signal deconvolution of the 190 subject sera, gave predictions that were 58% correct. 
When individuals were randomly assigned to either the training group (70% of subjects) or 
the validation group (30%) and the model applied, the predictions were correct for 62% of 
patients in the former group and for only 53% of patients in the latter group. This is barely 
more than the 50% that would be obtained through random prediction. When whole-spectrum 
analysis was conducted on the 207 elements according to a previously described protocol1,2, 
the correctness of the prediction was 82%. However, it was 87% on the training group but 
only 53% in the independent validation group. 
Our results confirmed that, as suggested by Kirschenlohr et al.2, the achievable  
accuracy of the prediction of the NMR plasma results makes the technique unfeasible for 
clinical use. Kirschenlohr et al.2 obtained a low prediction accuracy predictability when they 
compared NMR data analyses to angiographic findings performed at the same time2, but, as 
shown here, it is even worse for the prediction of clinical events from baseline samples in type 
2 diabetic patients with high cardiovascular risk. We were not able to achieve patient 
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discrimination in the validation sample by using whole-spectrum analysis as described by 
Brindle et al.1, nor could we obtain it from Lorentzian lipid deconvolution. This may be due 
to over-fitting of the data, as Kirschenlohr et al.2 have suggested, but 190 samples represent a 
relatively large number of patients when compared to the population size used by Brindle et 
al.1 We applied the same experimental and analytical protocol and similar statistical analysis 
to spectra obtained for 120 hyperlipidemic subjects in samples collected before and after 
statin therapy. These analyses were part of a short-term clinical trial involving 
hypercholesterolemic men, as described in Le Moyec et al.5 The ability to discriminate 
samples before and after treatment was better with OSC/PLS-DA of Lorentzians areas than 
with whole-spectra analysis (correctness of the prediction in the 30% validation sample was 
86% and 72%, respectively), suggesting that only very stringent characteristics may be 
discriminated by NMR analysis, if the size of the population is adequate with respect to the 
number of parameters to be analyzed. 
Our work was not a replication study but was aimed at evaluating the relevance of this 
technique for the prediction of severe cardiovascular events in high-risk type 2 diabetic 
patients. Our conclusions are very similar to those of Kirschenlohr et al.2 As these authors 
concluded, the discriminatory capacity of multivariate analyses of NMR spectroscopic data is 
not high enough to render the technique feasible for clinical use. With respect to 
cardiovascular risk prediction, global statistical analyses, including classical biochemical and 
clinical risk factors at baseline, should be considered in addition to NMR data.  
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Table 1  Characteristics of subjects 
 
 
 
 
Cases Controls P-values 
Number of subjects  95 95 – 
Male/female 75/20 75/20 – 
Age (years) 69 ± 9 69±9 0.97 
BMI (kg/m²) 29.3 ± 4.6 29.2 ± 4.7 0.90 
Active smoker 16% 19% 0.61 
Percentage of patients 
with myocardial 
infarction history  
7% 4% 0.35 
Fasting glycemia 
(mM) 
9.9 ± 3.1 9.2 ± 2.8 0.12 
Glycated haemoglobin 
(HbA1c, %)  
7.8 ± 1.8 7.7 ± 1.6 0.80 
Total cholesterol (mM) 5.8 ± 1.2 5.6 ± 1.0 0.28 
HDL (mM) 1.2 ± 0.3 1.3 ± 0.4 0.30 
LDL (mM) 3.6 ± 0.9 3.4 ± 0.8 0.26 
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Percentage of patients 
taking cholesterol-
lowering drugs  
33% 36% 0.65 
Systolic blood pressure 
(mm Hg) 
146.5 ± 14.0 143.8 ± 14.2 0.19 
Diastolic blood 
pressure (mm Hg) 
82.8 ± 7.9 81.9 ± 8.8 0.48 
Hypertension  60% 54% 0.38 
 
Clinical and biological characteristics (mean ± s.d. or frequency) of the type 2 diabetic patients 
included in the case-control study nested in the placebo arm of the DIABHYCAR trial, and 
comparisons between the patients who either presented a fatal/nonfatal acute myocardial infarction or 
underwent sudden death during the 4-year follow-up, and patients who did not present any such event  
(P-values). 
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